Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. However, the management discussed significant CapEx plans of around Rs. 40-45 crores annually for FY23, FY24, and FY25, implying potential funding needs. Themis Lifestyle Private Limited (TSPL) is obligated to pay Themis Medicare Limited Rs. 125 crores as part of a demerger process, which may involve cash and/or share certificates. Themis Medicare, as the holding company, will support TSPL in this activity. No direct statements regarding new debt or equity fundraising rounds wer

Any current/future capex/capital investment/strategic investment?

Themis Medicare plans CapEx of around Rs. 40-45 crores per year for FY23, FY24, and FY25. Significant CapEx is required for scaling up the API business to achieve next-level growth. The company is preparing for inorganic growth in API by creating a subsidiary to allow focused expansion. No plans to develop an online portal for hospital orders; existing distribution systems by specialized companies are preferred. Partnership and inorganic opportunities, especially in the hospital business, are being explored to drive growth. R&D investments continue with a focus on new drug delivery systems, AP

Future growth expectations in sales/revenue/volumes?

Themis Medicare targets a 35% CAGR in consolidated revenue over the next 3 years, aiming to reach around Rs. 1,000 crores. Current year revenue is expected to be close to last year’s level (~Rs. 400 crores), without COVID-related spikes. Growth drivers include: - Significant increase in hospital business through expanded and more productive sales teams. - Increasing revenues from API business backed by new product launches and capacity expansions. - Strategic partnerships and inorganic growth opportunities, especially in hospital and API segments. New products, particularly i

Future growth expectations in earnings/operating earnings/profits/EPS?

Themis Medicare aims for a consolidated revenue CAGR of 35% over the next 3 years, targeting around Rs. 1,000 crores top line. Q3 FY23 revenues declined YoY due to COVID-related revenue drop, but PAT grew by 6.86% YoY. EBITDA margin target is to improve from current ~20% to about 25% driven mainly by operating leverage and improved productivity without significant headcount increases. New finished dosage form products are expected to have gross margins of 40-70%, contributing to margin expansion. New API launches target gross contribution of about 50%, adding to EBITDA growth. R&D efforts are

Themis Medicare LtdQ3 FY23Pharmaceuticals & Biotechnology

Themis Medicare Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹113Market Cap: ₹1.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Themis Medicare targets a 35% CAGR in consolidated revenue over the next 3 years, aiming to reach around Rs. 1,000 crores.
Current year revenue is expected to be close to last year’s level (~Rs. 400 crores), without COVID-related spikes.
Growth drivers include:
- Significant increase in hospital business through expanded and more productive sales teams.
- Increasing revenues from API business backed by new product launches and capacity expansions.
- Strategic partnerships and inorganic growth opportunities, especially in hospital and API segments.
New products, particularly in APIs, are planned to launch quarterly, starting to contribute to topline within 6 months of exhibit batches.
Emphasis on organic growth supported by selective inorganic expansions to sustain targeted high growth.

Margin guidance

Category 1

Themis Medicare aims for a consolidated revenue CAGR of 35% over the next 3 years, targeting around Rs. 1,000 crores top line.
Q3 FY23 revenues declined YoY due to COVID-related revenue drop, but PAT grew by 6.86% YoY.
EBITDA margin target is to improve from current ~20% to about 25% driven mainly by operating leverage and improved productivity without significant headcount increases.
New finished dosage form products are expected to have gross margins of 40-70%, contributing to margin expansion.
New API launches target gross contribution of about 50%, adding to EBITDA growth.
R&D efforts are expected to begin generating revenues roughly 6 months after exhibit batches, starting next quarter.
ROCE guidance for FY23 is around 25% to 30%, reflecting improved capital efficiency.
The growth strategy includes hospital business expansion, API business scaling, partnerships, and inorganic opportunities.

See what Themis Medicare Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript.
However, the management discussed significant CapEx plans of around Rs. 40-45 crores annually for FY23, FY24, and FY25, implying potential funding needs.
Themis Lifestyle Private Limited (TSPL) is obligated to pay Themis Medicare Limited Rs. 125 crores as part of a demerger process, which may involve cash and/or share certificates. Themis Medicare, as the holding company, will support TSPL in this activity.
No direct statements regarding new debt or equity fundraising rounds were made during the call.
The company is also preparing for inorganic growth and significant investments, especially in the API business, which may imply future capital requirements, but no clear plans have been announced.

Order book

The transcript does not explicitly mention Themis Medicare Limited's current or expected order book or pending orders details. However, relevant points related to business outlook and related operational factors include: - Hospital business expected to be in line with last year, excluding Rs. 65 crore COVID-related one-time orders. - New intensive care division to be fully operational by March 2023, boosting hospital business. - API segment faced challenges due to increased input costs, leading to strategic reduction in production of a key API to meet contractual commitments. - Alternative manufacturing route for key API planned by end of Q4 FY23 or early next financial year. - Three additional APIs expected to go into commercial production by Q2 or Q3 FY24. - Strong R&D pipeline with plans to take 2 exhibit batches per quarter to increase product launches and revenues. No specific figures on order book or pending orders were disclosed in the call transcripts.

See what Themis Medicare Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Themis Medicare plans CapEx of around Rs. 40-45 crores per year for FY23, FY24, and FY25.
Significant CapEx is required for scaling up the API business to achieve next-level growth.
The company is preparing for inorganic growth in API by creating a subsidiary to allow focused expansion.
No plans to develop an online portal for hospital orders; existing distribution systems by specialized companies are preferred.
Partnership and inorganic opportunities, especially in the hospital business, are being explored to drive growth.
R&D investments continue with a focus on new drug delivery systems, APIs, and generic injectables, targeting new product launches every quarter to support revenue growth.

Track Themis Medicare Ltd — get its next earnings analysis in your feed

How does Themis Medicare Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisThemis Medicare Ltd

Rev 2Mar 1

See where Themis Medicare Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Themis Medicare Ltd rank in Pharmaceuticals & Biotechnology?

Compare Themis Medicare Ltd against every Pharmaceuticals & Biotechnology company (Q3 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Themis Medicare Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →